BridgeBio have significantly advanced this course of the innovative therapy for amyloid heart disease, employing the investigational drug. Early clinical data indicates potential improvements for those diagnosed from this severe condition. The emphasis highlights the company’s focus to treating critical patient needs in the cardiology arena. Att